Fusion protein technologies for biopharmaceuticals : applications and challenges / [electronic resource]
edited by Stefan R. Schmidt.
- Hoboken, New Jersey : John Wiley & Sons, ©2013.
- 1 online resource.
Includes bibliographical references and index.
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
9781118354582 1118354583 9781118354575 1118354575 9781118354568 1118354567 9781118354599 1118354591 9781299241954 1299241956
2012040270
Biopharmaceutics.
Pharmaceutical biotechnology.
Drug carriers.
Immunotoxins--Therapeutic use.
Protein engineering.
Recombinant fusion proteins--Therapeutic use.
MEDICAL--Pharmacology.
Biopharmaceutics.
Pharmaceutical biotechnology.
Recombinant Fusion Proteins--therapeutic use.
Drug Carriers.
Immunotoxins--pharmacokinetics.
Immunotoxins--therapeutic use.
Protein Engineering.
Recombinant Fusion Proteins--pharmacokinetics.
Electronic books.
Electronic books.
RM301.4 / .F87 2013
615.7
QU 450
Includes bibliographical references and index.
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
9781118354582 1118354583 9781118354575 1118354575 9781118354568 1118354567 9781118354599 1118354591 9781299241954 1299241956
2012040270
Biopharmaceutics.
Pharmaceutical biotechnology.
Drug carriers.
Immunotoxins--Therapeutic use.
Protein engineering.
Recombinant fusion proteins--Therapeutic use.
MEDICAL--Pharmacology.
Biopharmaceutics.
Pharmaceutical biotechnology.
Recombinant Fusion Proteins--therapeutic use.
Drug Carriers.
Immunotoxins--pharmacokinetics.
Immunotoxins--therapeutic use.
Protein Engineering.
Recombinant Fusion Proteins--pharmacokinetics.
Electronic books.
Electronic books.
RM301.4 / .F87 2013
615.7
QU 450